A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome

Summary

This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Cryopyrin-Associated Period Syndrome (CAPS). Approximately 10 patients will take VTX2735 Dose A or VTX2735 Dose B. The study consists of a screening/washout period of up to 28 weeks, a 2 week treatment period, a treatment withdrawal period of up to 2 weeks, another 2 week treatment period, and a 4 week follow up period. The maximum length of treatment is 4 weeks.

Timeline

Start

2023-03-18

Primary completion

2024-03-06

Completion

2024-03-06

Drugs

Indications